中國的糖尿病市場分析 是由出版商RNCOS E-Services Pvt. Ltd.在2011年07月所出版的。
這份英文市場調查報告書包含50 Pages 價格從美金800起跳。
中國糖尿病為常見的疾病，在2010年患者數量也達到了9200萬人。一般認為由於西化的飲食和人口高齡化使得糖尿病患者劇增。而這個結果，預計會讓中國國內的糖尿病口服藥的市場在2011-2014年以年平均5.3％向上成長。
本報告提供中國的糖尿病相關市場的相關調查，糖尿病的蔓延狀況，市場促進與阻礙因素，相關藥品與設備市場的最新趨勢，政府的政策，同時也包含主要企業簡介，彙整以上種種資訊，為您概述為以下內容。
第1章 分析師的見解
第2章 分析方法
第3章 患者簡介分析
第4章 成本的意義
第5章 市場促進·阻礙因素
- 肥胖症發生率的上升
- 全球大企業投資增加
- 產業內的企業整合
- 新的胰島素注入設備
第6章 糖尿病藥物市場
第7章 胰島素注入設備市場
第8章 血糖偵測設備市場
第9章 政府的法規與倡議
第10章 主要企業
- Novo Nordisk
- Eli Lilly
- Sanofi-Aventis
- Bayer
- Merck & Co.
- Tianjin Takeda Pharmaceuticals Co Ltd
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Wanbang Biopharmaceuticals
圖表一覽
Abstract
Diabetes has emerged as one of the most common diseases in China, affecting
over 92 Million people at the end of 2010. The country has a significant share
in the diabetes market globally with a major share of diabetics in the country
affected with type-II diabetes. Factors, such as incidence of diabetes
associated with Western diets and an aging population has contributed to such
a stupendous escalation in the diabetes population in China. Consequently, the
oral diabetes drug market of China is anticipated to grow at a CAGR of around
5.3% during 2012 - 2014.
Our report has also found that, one of the main factors for the growth of the
market is the entry of numerous foreign pharmaceutical giants in the diabetes
market. The main factor for the interest of foreign players in the country' s
diabetes market is the huge customer base, cheap labor and land cost provided
by the country. Besides, increasing prevalence of obesity has played an
important role in surging the number of diabetic patients in the country,
which in turn, has fuelled the diabetes market in the country.
It has been believed that, diabetes will have major implications for people' s
health and life expectancy. It will result in out-of-control China healthcare
costs, placing growing strain on the budgets of families, employers, states,
and the government. Studies carried out by WHO have shown that, China will
lose around US$ 557.7 Billion of national income to diabetes and
cardiovascular disease during 2005 - 2015.
Our report "China Diabetes Market Analysis" highlights the Chinese diabetes
market by segmenting it into - oral diabetic drug market, insulin drug market,
insulin delivery devices market, and glucose monitoring market. Each of these
segments have been thoroughly studied and analyzed in the report. Moreover,
the report provides an overview of the patient profile and cost implications
of diabetes in the country, which will help clients in identifying the future
demand scenario.
The report studies the current development process and its effects on various
segments of the industry. The research contains exhaustive information
regarding the market players, government initiatives, and patient profile that
will help clients in formulating market strategies and assess opportunity
areas in the Chinese diabetes market.
Table of Contents
1. Analyst View
2. Research Methodology
3. Patient Profile Analysis
4. Cost Implications
5. Market Drivers and Trends
- 5.1 Rising Prevalence of Obesity
- 5.2 Increasing Investment from Global Giants
- 5.3 Consolidation of the Industry
- 5.4 Emerging Insulin Delivery Devices
- 5.4.1 Oral Insulin
- 5.4.2 Insulin Jet Injectors
6. Diabetes Drugs Market
- 6.1 Oral Diabetic Drugs Market
- 6.2 Insulin Drugs Market
7. Insulin Delivery Devices Market
- 7.1 Insulin Pump
- 7.2 Insulin Pen
- 7.3 Insulin Syringes
8. Glucose Monitoring Devices Market
- 8.1 Self Monitoring Blood Glucose (SMBG) Devices
9. Government Regulations and Initiatives
10. Key Players
- 10.1 Novo Nordisk
- 10.2 Eli Lilly
- 10.3 Sanofi-Aventis
- 10.4 Bayer
- 10.5 Merck & Co.
- 10.6 Tianjin Takeda Pharmaceuticals Co Ltd
- 10.7 Tonghua Dongbao Pharmaceutical Co., Ltd.
- 10.8 Wanbang Biopharmaceuticals
List of Figures:
- Figure 3-1: Prevalence of Diabetes (%), 2010 & 2030
- Figure 3-2: Prevalence of Impaired Glucose Tolerance (%), 2010 & 2030
- Figure 3-3: Number of Diabetic Population (Million), 2010 & 2030
- Figure 4-1: India & China - National Income Loss by Diabetes and
Cardiovascular Diseases (Billion US$), 2005 to 2015
- Figure 6-1: Oral Diabetic Drugs Market (Billion US$), 2010-2014
- Figure 6-2: Insulin Drugs Market (Billion US$), 2010-2014
- Figure 6-3: Insulin Market Share by Player (2010)
- Figure 7-1: Insulin Pump Market (Million US$), 2010-2014
- Figure 7-2: Insulin Pen Market (Million US$), 2010-2014
- Figure 7-3: Insulin Syringes Market (Billion US$), 2010-2014
- Figure 8-1: SMBG Devices Market (Million US$), 2010-2014
